Prostate Cancer

Ezra’s Prostate AI is the first to ever by cleared by the FDA Ezra , the NY-based startup transforming early cancer screening using MRI, announced that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first Prostate AI to ever be cleared by the FDA . Due to the increased efficiency that Prostate AI will generate for partner radiologists, Ezra is decreasing the price of the Ezra Prostate Scan by 15%, to  $575 . “Over the past two years, our team has worked tirelessly on building Ezra’s Prostate AI and I’m thrilled to bring it to our imaging partners across the US,” said  Emi Gal , CEO and co-founder of Ezra. “We will continue to work towards making the interpretation of prostate MRI scans faster and more affordable, in order to support the millions of men who are at risk of prostate cancer.” Recomme...

Dr. Ramneet Kaur knows two things about triple negative breast cancer. It is aggressive and only responds to chemotherapy until it becomes resistant. "Cancer cells are very smart," said the lecturer of biology at the University of North Georgia (UNG). "You can target one pathway to kill them, and they activate another pathway." To help breast cancer patients, Kaur received a Center for Undergraduate Research and Creative Activities (CURCA) mini-grant in 2017 to explore the use of natural products to treat triple negative breast cancer cells. She tested many natural products and found turmeric, ginger, lemon peel, grapefruit and the herb ashwagandha to be effective in killing triple negative breast cancer cells. In 2019, she received a professional development grant to check the effects of natural products on the triple negative breast cancer cells that were resistant to the chemotherapy drug, docetaxel. Based on her research and its results, Kaur applied for an...

Rutgers researchers have discovered human gene markers that work together to cause metastatic prostate cancer – cancer that spreads beyond the prostate. The study, published in the journal  Nature Cancer , explored prostate cancer cells from people and mice and found a wide collaboration among 16 genes that leads to metastasis, which often leads to treatment challenges. The gene markers identified can predict if a prostate cancer patient has a high probability of developing metastasis, including bone. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States with a five-year relative survival rate of near 100 percent when diagnosed early. Metastatic prostate cancer has a five-year survival rate of 30 percent. Current therapeutics like first- and next- generation anti-androgens that target male sex hormones alongside radiation, chemotherapy and others are not always effective, and it’s impossible to predict which patients are at ris...

Oct. 19 (UPI) -- Scientists say they now may be able to identify men with prostate cancer at risk for it to spread, according to an article published Monday by the journal Nature Cancer. In their analysis of prostate cancer cells from people and mice, researchers from Rutgers Cancer Institute of New Jersey found that a "collaboration among 16 genes" leads to metastasis, meaning that the cancer has spread to one or more other parts of the body. Advertisement The genes, or proteins, they identified can predict if a prostate cancer patient has a high probability of developing metastasis, including bone cancer, the researchers said. "People diagnosed with prostate cancer should now be screened for the protein markers [we] discovered to help determine their risk of developing metastatic prostate cancer," study co-author Antonina Mitrofanova, an assistant professor at the Rutgers School of Health Professions, said in a statement. Prostate cancer is the second l...

Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia Rutgers researchers have discovered human gene markers that work together to cause metastatic prostate cancer—cancer that spreads beyond the prostate. The study, published in the journal Nature Cancer , explored prostate cancer cells from people and mice and found a wide collaboration among 16 genes that leads to metastasis, which often leads to treatment challenges. The gene markers identified can predict if a prostate cancer patient has a high probability of developing metastasis, including bone. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States with a five-year relative survival rate of near 100 percent when diagnosed early. Metastatic prostate cancer has a five-year survival rate of 30 percent. Current therapeutics like first- and next- generation anti-androgens that target male sex hormones alongside radiation, c...

Last month, the CDC launched a prostate cancer information program with a uniquely digital face: a "virtual human" named Nathan who speaks with men about screening and treatment. "Talk to Someone About Prostate Cancer" takes the form of an in-browser interactive video developed by health simulation company Kognito, where Nathan introduces himself and prompts the viewer by asking how confident they are talking to their provider about prostate cancer screening. Users indicate their response by clicking one of several text responses, prompting a relevant reply, and kicking off a series of question and answer conversation trees. Accompanying the interactive tool on the CDC's site is a resource center with more information about the disease, relevant health tips, statistics, screening risks, and other basic guidance and recommendations. The public health agency notes that the patient-facing tools are also designed for use by providers during a clinical encounter t...

A first-of-its-kind study in the UK is aiming to solve the mystery of why black men develop prostate cancer at twice the rate of other men in the UK. The PROFILE study will look at the genes of men of African and Caribbean descent to see if they can learn to predict prostate cancer risk, and find better ways of diagnosing and treating the disease. In the UK, one in four black men will be diagnosed with prostate cancer in their lifetime, double the one in eight risk faced by all men. This Black History Month, the hope is to raise awareness of this increased risk for black men and encourage men who are eligible to take part in the study, which has resumed after being forced to temporarily halt recruitment due to the Covid-19 pandemic. The study is currently open to men aged 40-69, who are of African or Caribbean descent and haven’t previously had prostate cancer. It will continue to recruit men until 1 June 2021. Understanding black men's higher risk To help them understand bla...